Skip to main content
OpenTrials
Completed

NCT Number: NCT05552508

BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging

This study will assess the effects of benralizumab on airway dynamics in severe eosinophilic asthma in terms of quantitative computed tomography (CT)-derived measurements of pulmonary structure and function using the Functional Respiratory Imaging (FRI) platform.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Eosinophilia Hematologic Diseases Hemic and Lymphatic Diseases Hypereosinophilic Syndrome Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Leukocyte Disorders Lung Diseases Lung Diseases, Obstructive Pulmonary Eosinophilia Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Research Site, Clayton, Australia

Loading trial locations.

About this study

This is a phase IV, interventional single group, open-label, uncontrolled, prospective, multicenter clinical trial.

This study will be conducted in male and female participants ≥18 years old with established severe eosinophilic asthma as defined by European Respiratory Society (ERS)/American Thoracic Society (ATS) clinical guidelines inadequately controlled by treatment with Inhaled Corticosteroids-Long-acting β2 agonists (ICS-LABA) with or without oral corticosteroids (OCS) or other asthma controller medications.

Each participant will participate in the study for a minimum of 15 weeks and up to 23 weeks.

This study will comprise of:

Screening visit (V0) Visit 1 (V1; week 0; within 1 to 21 days of screening) Visit 2 (V2; week 4 ± 5 days) Visit 3 (V3; week 8 ± 5 days) Visit 4 (V4; week 13 ± 5 days) Follow-up (2 weeks [± 7 days] after V4) - Phone call follow-up. Participants will be discharged from the study after the phone call follow-up is completed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants who are diagnosed with asthma with documented reversibility post-bronchodilator or salbutamol either historical or at Visit 0 (V0).
  • Participants who have documented treatment with ICS and LABA for ≥ 3 months prior to V0 with or without oral corticosteroids and additional asthma controllers.
  • Participants who have documented peripheral blood eosinophil count ≥ 300 cells/μL at V0, or if Oral Corticosteroids (OCS)-dependent, a documented peripheral blood eosinophil count ≥ 150 cells/μL at V0.
  • Participants who have had a minimum of 2 exacerbations in the last 12 months prior to V0.
  • Participants who have pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) ≤ 70% at Visit 0 (V0).
  • Participants who have pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1) < 80% of predicted at V0.
  • Participants who can perform acceptable and repeatable spirometry.
  • Participants who can withhold asthma maintenance medication for at least 12 hours prior to V0, 1 and 4 where spirometry and/or Computed Tomography (CT) scan procedures will be performed except for once-a-day dosage where 24 hours will be required.
  • Female participants who have a negative pregnancy test prior to administration of the investigational product (IP) and high-resolution CT scan and must agree to use a highly effective method of birth control from randomization throughout the study duration and within 12 weeks after last dose of IP.

Exclusion criteria

  • Participants who are unstable or who experienced an exacerbation/infection in the 6 weeks before V0.
  • Participants with acute upper or lower airway infection in the 6 weeks before V0.
  • Participants diagnosed with clinically important pulmonary disease other than asthma, or participants who have ever been diagnosed with pulmonary or systemic disease, other than asthma that are associated with elevated peripheral eosinophil count.
  • Receipt of any biologic products for asthma within 4 months or 5 half-lives prior to V0 whichever is longer.
  • History or current use of chronic (i.e., > 4 weeks) immunosuppressive medication.
  • History of lung volume reduction surgery, lung resection, thermal bronchoplasty at any time before visit 0 (V0) or on active phase of pulmonary rehabilitation.
  • Participants with current malignancy or history of malignancy.
  • History of other clinically significant disease or abnormality.
  • Participants with positive Hepatitis B, C or HIV.
  • Participants with:

Positive COVID-19 test at V0, COVID-19 disease within 6 weeks before V0 or History of severe COVID-19 disease at any time, defined by the need for Intensive Care Unit stay or Mechanical Ventilation (invasive or non-invasive).

Treatment and study plan

Benralizumab

Combination Product

Participants will receive benralizumab subcutaneously.

Other names: Fasenra

Primary outcomes

  1. Change From Baseline in Untrimmed Total Mucus Volume at TLC

    Time frame: Baseline and Week 13

    Change from baseline in airway dynamics after 13 weeks following treatment with benralizumab, using total mucus volume (specific airway volume) at total lung capacity (TLC) measurements from untrimmed airways was assessed.

Secondary outcomes

  1. Change From Baseline in Untrimmed Total Mucus Plugs Score at TLC

    Time frame: Baseline and Week 13

    Change from baseline in untrimmed total mucus plugs score at TLC was assessed. Mucus plugs was scored with a scoring system similar to that by Dunican et al. with the Severe Asthma Research Program (SARP) based on bronchopulmonary segmental anatomy. The mucus score was calculated by counting the number of bronchopulmonary segments which contained 1 or more mucus plug, up to a maximum score of 18 corresponding to the 18 bronchopulmonary segments present in most people. In this system, a mucus plug is defined as a complete occlusion of the airway visible at TLC. Each bronchopulmonary segment is given a score of 1 (mucus plug[s] present) or 0 (mucus plug[s] absent). The segment scores of each lobe are summed to generate a total mucus score for both lungs, yielding a mucus score ranging from 0-18. Higher scores indicate worse outcome.

  2. Change From Baseline in Untrimmed Total Air Trapping at FRC

    Time frame: Baseline and Week 13

    Change from baseline in untrimmed total air trapping at FRC was assessed.

  3. Change From Baseline in Trimmed Distal Airway Wall Volume at TLC

    Time frame: Baseline and Week 13

    Change from baseline in trimmed distal airway wall volume at TLC was assessed. Change from baseline in airway dynamics at Week 13 following treatment with benralizumab as measured by secondary FRI endpoints, irrespective of participants characteristics was assessed.

  4. Change From Baseline in Untrimmed Distal Airway Volume at TLC

    Time frame: Baseline and Week 13

    Change from baseline in untrimmed distal airway volume at TLC was assessed.

  5. Change From Baseline in Untrimmed Distal Airway Volume at Functional Residual Capacity (FRC)

    Time frame: Baseline and Week 13

    Change from baseline in untrimmed distal airway volume at FRC was assessed.

  6. Change From Baseline in Untrimmed Total Lung Volume at TLC

    Time frame: Baseline and Week 13

    Change from baseline in untrimmed total lung volume at TLC was assessed.

  7. Change From Baseline in Untrimmed Total Lung Volume at FRC

    Time frame: Baseline and Week 13

    Change from baseline in untrimmed total lung volume at FRC was assessed.

  8. Correlation Between Untrimmed Total Mucus Volume Measured at TLC and Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1)

    Time frame: At Baseline (Week 0)

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% confidence interval (CI) for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations.

    Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

  9. Correlation Between Untrimmed Total Mucus Plugs Score at TLC and Pre-BD FEV1

    Time frame: At Baseline (Week 0)

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations.

    Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

  10. Correlation Between Untrimmed Total Air Trapping at FRC and Pre-BD FEV1

    Time frame: At Baseline (Week 0)

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

  11. Correlation Between Trimmed Distal Airway Wall Volume at TLC and Pre-BD FEV1

    Time frame: At Baseline (Week 0)

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations.

    Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

  12. Correlation Between Untrimmed Distal Airway Volume at TLC and Pre-BD FEV1

    Time frame: At Baseline (Week 0)

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations.

    Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

  13. Correlation Between Untrimmed Distal Airway Volume at FRC and Pre-BD FEV1

    Time frame: At Baseline (Week 0)

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations.

    Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

  14. Correlation Between Untrimmed Total Lung Volume at TLC and Pre-BD FEV1

    Time frame: At Baseline (Week 0)

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations.

    Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

  15. Correlation Between Untrimmed Total Lung Volume at FRC and Pre-BD FEV1

    Time frame: At Baseline (Week 0)

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations.

    Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

  16. Correlation Between Untrimmed Total Mucus Volume Measured at TLC and Pre-bronchodilator Forced Vital Capacity (Pre-BD FVC)

    Time frame: At Baseline (Week 0)

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations.

    Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

  17. Correlation Between Untrimmed Total Mucus Plugs Score at TLC and Pre-BD FVC

    Time frame: At Baseline (Week 0)

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations.

    Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

  18. Correlation Between Untrimmed Total Air Trapping at FRC and Pre-BD FVC

    Time frame: At Baseline (Week 0)

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations.

    Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

  19. Correlation Between Trimmed Distal Airway Wall Volume at TLC and Pre-BD FVC

    Time frame: At Baseline (Week 0)

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations.

    Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

  20. Correlation Between Untrimmed Distal Airway Volume at TLC and Pre-BD FVC

    Time frame: At Baseline (Week 0)

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations.

    Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

  21. Correlation Between Untrimmed Distal Airway Volume at FRC and Pre-BD FVC

    Time frame: At Baseline (Week 0)

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations.

    Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

  22. Correlation Between Untrimmed Total Lung Volume at TLC and Pre-BD FVC

    Time frame: At Baseline (Week 0)

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations.

    Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

  23. Correlation Between Untrimmed Total Lung Volume at FRC and Pre-BD FVC

    Time frame: At Baseline (Week 0)

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations.

    Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

  24. Change From Baseline in Untrimmed Total Mucus Volume Measured at TLC With and Without Adjustment for Pre-BD FEV1

    Time frame: Baseline and Week 13

    The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).

  25. Change From Baseline in Untrimmed Total Mucus Plugs Score at TLC With and Without Adjustment for Pre-BD FEV1

    Time frame: Baseline and Week 13

    Relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1). Mucus plugs was scored with a scoring system similar to that by Dunican et al. with SARP based on bronchopulmonary segmental anatomy. Mucus score was calculated by counting number of bronchopulmonary segments which contained 1 or more mucus plug, up to a maximum score of 18 corresponding to the 18 bronchopulmonary segments present in most people. In this system, a mucus plug is defined as a complete occlusion of airway visible at TLC. Each bronchopulmonary segment is given a score of 1 (mucus plug present) or 0 (mucus plug absent). The segment scores of each lobe are summed to generate a total mucus score for both lungs, yielding a mucus score ranging from 0-18. Higher scores = worse outcome.

  26. Change From Baseline in Untrimmed Total Air Trapping at FRC With and Without Adjustment for Pre-BD FEV1

    Time frame: Baseline and Week 13

    The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).

  27. Change From Baseline in Trimmed Distal Airway Wall Volume at TLC With and Without Adjustment for Pre-BD FEV1

    Time frame: Baseline and Week 13

    The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).

  28. Change From Baseline in Untrimmed Distal Airway Volume With and Without Adjustment for Pre-BD FEV1

    Time frame: Baseline and Week 13

    The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).

  29. Change From Baseline in Untrimmed Total Lung Volume With and Without Adjustment for Pre-BD FEV1

    Time frame: Baseline and Week 13

    The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).

  30. Change From Baseline in Untrimmed Total Mucus Volume Measured at TLC With and Without Adjustment for Pre-BD FVC

    Time frame: Baseline and Week 13

    The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).

  31. Change From Baseline in Untrimmed Total Mucus Plugs Score at TLC With and Without Adjustment for Pre-BD FVC

    Time frame: Baseline and Week 13

    Relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC). Mucus plugs was scored with a scoring system similar to that by Dunican et al. with SARP based on bronchopulmonary segmental anatomy. Mucus score was calculated by counting number of bronchopulmonary segments which contained 1 or more mucus plug, up to a maximum score of 18 corresponding to the 18 bronchopulmonary segments present in most people. In this system, a mucus plug is defined as a complete occlusion of airway visible at TLC. Each bronchopulmonary segment is given a score of 1 (mucus plug present) or 0 (mucus plug absent). The segment scores of each lobe are summed to generate a total mucus score for both lungs, yielding a mucus score ranging from 0-18. Higher scores = worse outcome.

  32. Change From Baseline in Untrimmed Total Air Trapping at FRC With and Without Adjustment for Pre-BD FVC

    Time frame: Baseline and Week 13

    The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).

  33. Change From Baseline in Trimmed Distal Airway Wall Volume at TLC With and Without Adjustment for Pre-BD FVC

    Time frame: Baseline and Week 13

    The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).

  34. Change From Baseline in Untrimmed Distal Airway Volume With and Without Adjustment for Pre-BD FVC

    Time frame: Baseline and Week 13

    The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).

  35. Change From Baseline in Untrimmed Total Lung Volume With and Without Adjustment for Pre-BD FVC

    Time frame: Baseline and Week 13

    The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).

  36. Number of Participants With Adverse Events (AEs)

    Time frame: From screening (Day -21) to follow-up (up to 1.9 years)

    The safety and tolerability of benralizumab was assessed.

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

BURAN: Effects of Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging Parameters

Acronym: BURAN

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Sep 23, 2022
Registry last updated
Mar 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.